These authors contributed equally to this work.
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma
Version of Record online: 28 FEB 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 59, Issue 4, pages 1577–1590, April 2014
How to Cite
Fuchs, B. C., Hoshida, Y., Fujii, T., Wei, L., Yamada, S., Lauwers, G. Y., McGinn, C. M., DePeralta, D. K., Chen, X., Kuroda, T., Lanuti, M., Schmitt, A. D., Gupta, S., Crenshaw, A., Onofrio, R., Taylor, B., Winckler, W., Bardeesy, N., Caravan, P., Golub, T. R. and Tanabe, K. K. (2014), Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology, 59: 1577–1590. doi: 10.1002/hep.26898
Potential conflict of interest: Dr. Winckler owns stock in Novartis.
Supported by the National Institutes of Health (grant numbers K01 CA140861 to B.C.F., R01 DK099558 to Y.H., and R01 CA076183 to K.K.T.); the Massachusetts General Hospital Executive Committee on Research Fund for Medical Discovery to B.C.F.; Aid for Cancer Research to B.C.F.; the Howard Hughes Medical Institute to T.R.G.; and the Tucker Gosnell Center for Gastrointestinal Cancers to K.K.T.
- Issue online: 24 MAR 2014
- Version of Record online: 28 FEB 2014
- Accepted manuscript online: 21 OCT 2013 12:30PM EST
- Manuscript Accepted: 10 OCT 2013
- Manuscript Received: 22 FEB 2013
- Mount Sinai School of Medicine, New York, NY
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.